Hepatic pseudolymphoma: a clinicopathological study of five cases and review of the literature

Zen, Yoh; Fujii, Tozo; Nakanuma, Yasuni

doi:10.1038/modpathol.2009.165

Cited by 60 publications

(51 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present case is the first report of spontaneous complete regression of a pancreatic pseudolymphoma. There have been a few case reports that have delineated spontaneous diminution in size or disappearance of pseudolymphoma [10,13], and in some cases malignant transformation of pseudolymphoma into lymphoma has been suggested [14,15].…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Spontaneously complete regression of pseudolymphoma of the remnant pancreas after pancreaticoduodenectomy

Nakata¹,

Amano²,

Matsuoka³

et al. 2012

Pancreatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

“…Multiple pseudolymphoma has been observed in the lung in 36% of cases and in the liver in 19% of cases [9,10]. Multiple lesions of pancreatic islet cell tumors occur at a rate of approximately 5% and are mostly associated with multiple endocrine neoplasm I (MEN I) [11].…”

Section: Discussionmentioning

confidence: 99%

Spontaneously complete regression of pseudolymphoma of the remnant pancreas after pancreaticoduodenectomy

Nakata¹,

Amano²,

Matsuoka³

et al. 2012

Pancreatology

View full text Add to dashboard Cite

“…Unlike ISC, hilar duct involvement is uncommon. Histologically, this condition is more lymphoid in appearance with no increases in the number of IgG4-positive plasma cells [81].…”

Section: Hepatic Pseudolymphomamentioning

confidence: 99%

“…This is another mass-forming inflammatory condition in the liver [81]. Patients with hepatic pseudolymphoma sometimes have autoimmune diseases outside the liver or a history of malignancy.…”

Section: Hepatic Pseudolymphomamentioning

confidence: 99%

IgG4-related sclerosing cholangitis: all we need to know

2016

Self Cite

View full text Add to dashboard Cite

Our knowledge and experience of IgG4-related sclerosing cholangitis (ISC) have expanded in the last decade. ISC is one of the common organ manifestations of IgG4-related disease (IgG4-RD); approximately 60 % of patients with this systemic condition have ISC in the proximal and/or distal bile ducts. ISC needs to be discriminated from primary sclerosing cholangitis, cholangiocarcinoma, and other rare forms of lymphoplasmacytic cholangiopathy (e.g., follicular cholangitis and sclerosing cholangitis with granulocytic epithelial lesions). Its diagnosis requires a multidisciplinary approach, in which serology, histology, and imaging play crucial roles. Treatments with high-dose corticosteroids typically lead to the rapid and consistent induction of disease remission. Another promising therapeutic approach is B-cell depletion with rituximab. Although disease relapse is relatively common, provided that appropriate treatments are administered, ISC is considered a ''benign'' disease with a low risk of liver failure and biliary malignancy. Its molecular pathology is characterized by Th2-dominant immune reactions, regulatory T-cell activation, and CCL1-CCR8 interactions. Particular subsets of B cells such as plasmablasts and regulatory B cells also expand. A recent global proteomic study demonstrated that three significantly activated immunological cascades in ISC were all B-cell-or immunoglobulin-related (Fc-gamma receptormediated phagocytosis, B-cell receptor signaling pathway, and Fc-epsilon receptor I signaling pathway), suggesting the crucial roles of B cells in the underlying immune reactions. Despite the expansion of our knowledge of the pathophysiology of ISC, the exact role of IgG4 remains unclear. A better understanding of its immunopathology will offer some potential drug targets for this emerging biliary disease.

show abstract

“…These lesions exist in a spectrum with atypical lymphoid hyperplasia and lymphomas, and the distinction between these entities can be challenging. Additional cases of pseudolymphoma have been described in the liver [13], stomach [14], and breast [15]. In all of these sites, the major differential diagnosis for this entity is low-grade lymphoma.…”

Section: Discussionmentioning

confidence: 96%